Manuel Aivado has served as our President and CEO since September 2018. Prior to this, he was our SVP, CMO & CSO since September 2014. From March 2012 until September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 until March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. In addition, Dr. Aivado was an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for ten years, during which time he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology and medical oncology, and he received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.Read More
Don Dougherty joined Aileron as our SVP, CFO in June 2017, bringing more than 30 years of financial leadership experience. He founded Compound Capital Growth Investments (CCGrowth), LLC, a Boston investment firm focused on biopharmaceutical and other technology sectors, and has served as its president since 1999. Prior to that, Mr. Dougherty held senior positions at several investment firms, including Essex Investment Management (1994 to 1999), where he was a principal, portfolio manager and lead biotechnology analyst, and Putnam Investments (1986 to 1994), where he was a senior vice president and analyst in the Specialty Growth Group, which managed the Voyager, OTC Emerging Growth, and Health Sciences funds. He began his investment career at Endowment Management Research in 1983. Mr. Dougherty received a B.A. from Williams College, an M.B.A. from New York University, and his CPA and CFA early in his career.Read More
Vojo joined Aileron as our Chief Medical Officer in November 2018. He is a pharmaceutical industry executive with 20 years of hands-on experience in oncology drug development and medical affairs. Most recently, he was the CMO of Taiho Oncology, where he oversaw the reorganization and scaling of the U.S. and European R&D function to advance the development of the company’s clinical programs. Prior to Taiho, Dr. Vukovic held the CMO role at Synta Pharmaceuticals Inc. where he oversaw the company’s clinical programs, as well as biometrics, clinical operations, pharmacovigilance, regulatory and medical affairs. During his tenure at Synta, Dr. Vukovic led many early and late-stage clinical trials and their translational research activities, including biomarker discovery and validation. Prior to Synta, Dr. Vukovic was a Medical Director at Pfizer, where he was responsible for the development of sunitinib and axitinib in several oncology indications. He also was a member of the leadership team for Pfizer’s Oncology Radiotherapy Initiative. He received his MD from the University of Sarajevo, a MSc in Radiation Biology and a PhD in Tumor Biology from the University of Toronto.Read More
Allen Annis joined Aileron in November of 2007 and is our Senior Vice President of Research. He was previously Director of Technology Development at the Schering-Plough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS). Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study protein-drug interactions.
Dr. Annis received his B.S. in chemistry from the Georgia Institute of Technology and received his Ph.D. in chemistry from Harvard University.Read More